Molecular Targets of Anti-Glutamine Therapy with Acivicin in Cancer Cells

  • G. Weber
  • M. S. Lui
  • J. Seboldt
  • M. A. Faderan

Abstract

Systematic studies in this laboratory showed that there was an increase in the activities of enzymes of glutamine utilization of pyrimidine and purine biosynthesis in rat hepatomas of different growth rates and in other animal and human neoplasms. We also observed that there were increased concentrations of strategic nucleotides and deoxynucleotides in hepatomas and these elevations were linked with neoplastic transformation and progression (for overview see Weber [13]). Because of this increase in enzymic activities and nucleotide pools relating to glutamine utilization, an investigation was carried out to understand the impact of the anti-glutamine agent, acivicin, on the molecular targets, namely, key enzymic activities and concentrations of strategic nucleotides. These studies revealed a profound influence of the anti-glutamine agent on the enzymology and metabolism and survival of cancer cells [1, 3, 15].

Keywords

Sarcoma Glutamine Pyrimidine Purine Nucleoside 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aoki T, Sebolt J, Weber G (1982) In vivo inactivation of carbamoylphosphate synthetase II in rat hepatoma. Biochem Pharmacol 31: 927–932PubMedCrossRefGoogle Scholar
  2. 2.
    Cooney DA, Jayaram HN, Ryan JA, Bono VH (1974) Inhibition of L-asparagine synthetase by a new amino acid antibiotic with antitumor activity: L-(alphaS,5S)-alpha-amino-3-chloro-4,5-di- hydro-5-isoxazoleacetic acid (NSC-163501). Cancer Chemother Rep 58: 793–802Google Scholar
  3. 3.
    Denton J, Lui MS, Aoki T, Sebolt J, Weber G (1982) Rapid in vivo inactivation by acivicin of CTP synthetase, carbamoyl-phosphate synthetase II and amidophosphoribosyltransferase in hepatoma. Life Sci 30: 1073–1080PubMedCrossRefGoogle Scholar
  4. 4.
    Duceman BW, Jacob ST (1980) Transcriptionally active RNA polymerases from Morris hepatomas and rat liver. Biochem J 190: 781–789PubMedGoogle Scholar
  5. 5.
    Jackson RC, Lui MS, Boritzki TJ, Morris HP, Weber G (1980) Purine and pyrimidine nucleotide patterns of normal, differentiating and regenerating liver and of hepatomas in rats. Cancer Res 40: 1286–1291PubMedGoogle Scholar
  6. 6.
    Jayaram HN, Cooney DA, Ryan JA, Neil G, Dion RL, Bono VH (1975) L-(alphaS,5S)- alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother Rep 59: 481–491PubMedGoogle Scholar
  7. 7.
    Lui MS, Kizaki H, Weber G (1982) Biochemical pharmacology of acivicin in rat hepatoma cells. Biochem Pharmacol 31: 3469–3473PubMedCrossRefGoogle Scholar
  8. 8.
    Neil GL, Berger AE, Bhuyan BK, Blowers CL, Kuentzel SL (1978) Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino- 3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Adv Enzyme Regul 17: 375–398PubMedCrossRefGoogle Scholar
  9. 9.
    Neil GL, Berger AE, McPartland RP, Grindey GB, Bloch A (1979) Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Cancer Res 39: 852–856PubMedGoogle Scholar
  10. 10.
    Takeda E, Weber G (1981) Role of ribonucleotide reductase in expression of the neoplastic program. Life Sci 28: 1007–1014PubMedCrossRefGoogle Scholar
  11. 11.
    Tso JY, Bower SG, Zalkin H (1980) Mechanism of inactivation of glutamine amidotransferase by the antitumor drug L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). J Biol Chem 255: 6734–6738PubMedGoogle Scholar
  12. 12.
    Weber G (1977) Enzymology of cancer cells. Parts I and II. New Engl J Med 296:486–493, 541–551PubMedCrossRefGoogle Scholar
  13. 13.
    Weber G (1983) Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes Memorial Lecture. Cancer Res 43: 3466–3492PubMedGoogle Scholar
  14. 14.
    Weber G, Lui MS, Natsumeda Y, Faderan MA (1983) Salvage capacity of hepatoma 3924A and action of dipyridamole. Adv Enzyme Regul 21: 53–69PubMedCrossRefGoogle Scholar
  15. 15.
    Weber G, Prajda N, Lui MS, Denton JE, Aoki T, Sebolt J, Zhen Y-S, Burt ME, Faderan MA, Reardon MA (1982) Multi-enzyme-targeted chemotherapy by acivicin and actinomycin. Adv Enzyme Regul 20: 75–96PubMedCrossRefGoogle Scholar
  16. 16.
    Weiss GR, McGovren JP, Schade D, Kufe DW (1982) Phase I and pharmacological study of acivicin by 24-hour continuous infusion. Cancer Res 42: 3892–3895PubMedGoogle Scholar
  17. 17.
    Zhen Y-S, Lui MS, Weber G (1983) Effects of acivicin and dipyridamole on hepatoma 3924A cells. Cancer Res 43: 1616–1619PubMedGoogle Scholar

Copyright information

© Springer- Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • G. Weber
  • M. S. Lui
  • J. Seboldt
  • M. A. Faderan
    • 1
  1. 1.Laboratory for Experimental OncologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations